Antisense Therapeutics Ltd (ANP.AX): Watching the Stochastic RSI on This Stock – Buckeye Business Review

Antisense Therapeutics Ltd (ANP.AX): Watching the Stochastic RSI on This StockBuckeye Business ReviewTracking the numbers for Antisense Therapeutics Ltd (ANP.AX), we have recently spotted a possible bullish divergence using the 14 day Stochastic RSI. Traders may be following this reading to identify possible near-term strength or a possible reversal …and more »

Read More

Antisense Therapeutics Ltd (ANP.AX): Watching the Stochastic RSI on This Stock – Buckeye Business Review

Antisense Therapeutics Ltd (ANP.AX): Watching the Stochastic RSI on This StockBuckeye Business ReviewTracking the numbers for Antisense Therapeutics Ltd (ANP.AX), we have recently spotted a possible bullish divergence using the 14 day Stochastic RSI. Traders may be following this reading to identify possible near-term strength or a possible reversal …and more »

Read More

Ionis Brings Gastrointestinal Immune Therapy Candidate to Clinical-trial Stage – IBD News Today

IBD News TodayIonis Brings Gastrointestinal Immune Therapy Candidate to Clinical-trial StageIBD News TodayIonis used its proprietary antisense technology to develop IONIS-JBI 1-2.5 Rx. An antisense therapy consists of snythetic RNA that binds to the messenger RNA a faulty gene produces. The binding inactivates the messenger RNA, turning the gene off. This …Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For …Markets InsiderBiogen, Ionis to Continue SMA Therapy Development Partnership Under New AgreementSMA News TodayStifel Nicolaus Has Just Reaffirmed $50.0 Target Price Per Share on Ionis Pharmaceuticals Inc (IONS) stock, While …Frisco FastballNormanObserver.com -Zacks.comall 24 news articles »

Read More

Watching the Tape Move for Antisense Therapeutics (ATHJF) and Austin Exploration L (AUNXF) – Buckeye Business Review

Frisco FastballWatching the Tape Move for Antisense Therapeutics (ATHJF) and Austin Exploration L (AUNXF)Buckeye Business ReviewNeedle moving action has been spotted in Antisense Therapeutics (ATHJF) as shares are moving today on volatility -31.03% or -0.009 from the open. The OTC listed company saw a recent bid of 0.0200 and 10000 shares have traded hands in the session. When …Buy Them. Hold Them. Beat the Market.Zacks.comSociedad Quimica Y Minera S.a. – SQM – Stock Price Today – ZacksZacks Investment Researchall 57 news articles »

Read More

Neurology News – LWW Journals (blog)

Neurology NewsLWW Journals (blog)Antisense oligonucleotide therapy involving suppression of glial fibrillary acidic protein (GFAP) led to reduced pathology, microglial activation, and other disease markers in an engineered mouse model of Alexander disease, according to a proof-of …

Read More

Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For … – Markets Insider

Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For …Markets InsiderCARLSBAD, Calif., Dec. 21, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has earned a $5 million milestone payment associated with initiation and enrollment in a newly initiated Phase 1 clinical study of IONIS …and more »

Read More

Trading Spotlight on Antisense Therapeutics Ltd (ANP.AX) Shares – Hayden Business Journal

Trading Spotlight on Antisense Therapeutics Ltd (ANP.AX) SharesHayden Business JournalInvestors have taken notice of Antisense Therapeutics Ltd (ANP.AX) shares. They may be keeping a close watch on certain stock levels. A popular indicator among technical analysts that can help to measure the strength of market momentum is the Average …Share Spotlight on Antisense Therapeutics Ltd (ANP.AX): Price Moves 0.00%Morgan Researchall 2 news articles »

Read More

Biogen, Ionis looking for new SMA drugs following Spinraza’s success – BioPharma Dive

Business WireBiogen, Ionis looking for new SMA drugs following Spinraza’s successBioPharma DivePerpetual partners Biogen Inc. and Ionis Pharmaceuticals Inc. have entered another research collaboration that aims to their portfolio of spinal muscular atrophy (SMA) treatments beyond Spinraza. The collaboration will focus on identifying antisense …Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular AtrophyMarkets InsiderBiogen extends Ionis deal in SMAThe Pharma LetterWith AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMAEndpoints NewsNasdaq -Zacks Investment Research -American Consumer News, LLC -SEC.govall 60 news articles »

Read More

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy – Markets Insider

TrueBlueTribuneBiogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular AtrophyMarkets InsiderBiogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA …Biogen extends Ionis deal in SMAThe Pharma LetterBiogen, Ionis Ink Deal for Spinal Muscular Atrophy TherapiesNasdaqWith AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMAEndpoints NewsZacks Investment Research -SEC.gov -American Consumer News, LLCall 70 news articles »

Read More

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy – Business Wire (press release)

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular AtrophyBusiness Wire (press release)CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug …and more »

Read More

Progress made toward treatment for rare, fatal neurological disease – University of Wisconsin-Madison

University of Wisconsin-MadisonProgress made toward treatment for rare, fatal neurological diseaseUniversity of Wisconsin-MadisonIn the study, published this month in the Annals of Neurology, researchers introduced short, chemically modified fragments of DNA – called antisense oligonucleotides – into cells in laboratory dishes or directly into the brains of mice with Alexander …

Read More

What Kind of Picture Are the Technicals Painting For Antisense Therapeutics Ltd (ANP.AX)? Shares Tick -7.69% – Clawson News

What Kind of Picture Are the Technicals Painting For Antisense Therapeutics Ltd (ANP.AX)? Shares Tick -7.69%Clawson NewsNeedle moving action has been spotted in Antisense Therapeutics Ltd (ANP.AX) as shares are moving today on volatility -7.69% or $-0.002 from the open. The ASX listed company saw a recent bid of $0.024 and 50226 shares have traded hands in the session …and more »

Read More

Putting Antisense Therapeutics Ltd (ANP.AX) Under the Microscope: Stock Ticks -0.002 – Stock Press Daily

Putting Antisense Therapeutics Ltd (ANP.AX) Under the Microscope: Stock Ticks -0.002Stock Press DailyNeedle moving action has been spotted in Antisense Therapeutics Ltd (ANP.AX) as shares are moving today on volatility -7.69% or $-0.002 from the open. The ASX listed company saw a recent bid of $0.024 and 50226 shares have traded hands in the session …and more »

Read More

Ionis’ License Agreement for Huntington’s Disease Drug, IONIS-HTT … – Markets Insider

Third Force NewsIonis’ License Agreement for Huntington’s Disease Drug, IONIS-HTT …Markets InsiderCARLSBAD, Calif., Dec. 18, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its license agreement with Roche to develop and commercialize IONIS-HTTRx for the treatment of people with. Huntington’s disease (HD) has …Ionis earns $45M fee from Roche for rights to Huntington’s candidateSeeking Alphaall 4 news articles »

Read More

Splicing: Going in circles – Nature.com

Nature.comSplicing: Going in circlesNature.comThis was confirmed using an antisense oligonucleotide that targeted the intergenic region, which considerably reduced intergenic RNA levels and simultaneously decreased circPAIP2 levels. Thus, circRNA levels increase when the canonical splicing of the …

Read More

Trading Focus: Piotroski F Score Below Five on Shares of Antisense Therapeutics Ltd (ANP.AX) – Hayden Business Journal

Trading Focus: Piotroski F Score Below Five on Shares of Antisense Therapeutics Ltd (ANP.AX)Hayden Business JournalLooking at the numbers for Antisense Therapeutics Ltd (ANP.AX), we can now see that the Piotroski F Score reading is at five or lower. Tracking this signal, investors may be looking for signs of possible financial weakness. The Average Directional …and more »

Read More

Ionis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference – NB Herard

The Lincolnian OnlineIonis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare ConferenceNB HerardCARLSBAD, Calif., Dec. 15, 2017 — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January …Head to Head Analysis: Ionis Pharmaceuticals (NASDAQ:IONS) and Its RivalsWeek Heraldall 13 news articles »

Read More

Ionis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference – GuruFocus.com

The Lincolnian OnlineIonis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare ConferenceGuruFocus.comIonis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense …Head to Head Analysis: Ionis Pharmaceuticals (NASDAQ:IONS) and …Week Heraldall 15 news articles »

Read More

Antisense Therapy A Promising New Approach To Neurological Disease – ReliaWire

ReliaWireAntisense Therapy A Promising New Approach To Neurological DiseaseReliaWireA new treatment for Huntington’s disease – a deadly brain disorder – has successfully completed first-in-human trials. The drug lowered levels of the harmful huntingtin protein in the spinal fluid of patients who took part in the trial. Huntington’s …Roche licenses IONIS-HTTRX drug for treating Huntington’s diseaseThe Camping Canuck (press release) (blog)all 5 news articles »

Read More

Newly identified THOR gene could play a role in suppressing tumors – FierceBiotech

FierceBiotechNewly identified THOR gene could play a role in suppressing tumorsFierceBiotechThis approach, called antisense oligonucleotides, is already well-known in biotech. Atlantic Healthcare recently started a rolling submission for FDA approval of its antisense drug to treat inflammatory bowel disease, and Ionis recently licensed a …How defeating THOR could bring a hammer down on cancerEurekAlert (press release)all 5 news articles »

Read More